Incidence of Second Malignancy in Patients with Papillary Thyroid Cancer from Surveillance, Epidemiology, and End Results 13 Dataset
Table 3
Frequency and standardized incidence ratio of SPM by radiation and tumor size.
Site
Tumor size and radiation
No radiation
Yes radiation
No radiation
Yes radiation
& <1 cm
& <1 cm
& 1+ cm
& 1+ cm
Observed
O/E
Observed
O/E
Observed
O/E
Observed
O/E
All Sites
630
1.21#
267
1.40#
605
1.04
1110
1.15#
All sites excluding nonmelanoma skin
630
1.21#
265
1.40#
602
1.04
1107
1.15#
All solid tumors
564
1.20#
236
1.37#
531
1.01
981
1.13#
Oral cavity and pharynx
8
0.82
5
1.28
12
1.04
41
2.04#
Rectum and rectosigmoid junction
7
0.52
5
0.99
12
0.78
16
0.61#
Respiratory system
63
0.96
28
1.27
47
0.67#
97
0.84
Lung and bronchus
61
0.98
28
1.36
45
0.68#
97
0.9
skin
37
1.56#
19
2.00#
30
1.07
58
1.23
Melanoma of the skin
37
1.69#
17
1.93#
27
1.05
55
1.26
Male genital system
56
1.47#
36
1.88#
68
1.30#
131
1.34#
Prostate
56
1.50#
35
1.87#
66
1.30#
127
1.33#
Localized/regional
44
1.42#
24
1.64#
48
1.33
95
1.42#
Distant
1
3.26
1
1.37
6
3.26#
11
1.38
Urinary system
55
1.79#
25
2.19#
30
0.85
92
1.54#
Kidney renal pelvis
39
2.82#
16
3.05#
22
1.41
61
2.29#
Kidney
39
3.01#
16
3.23#
22
1.51
60
2.40#
Brain and other nervous system
3
0.52
1
0.45
8
1.18
22
1.91#
Endocrine system
46
2.73#
3
0.43
38
1.87#
23
0.65#
All lymphatic and hematopoietic diseases
59
1.45#
25
1.72#
61
1.32#
106
1.38#
Lymphoma
28
1.23
15
1.82#
32
1.24
44
1.01
Non-Hodgkin lymphoma
27
1.29
14
1.87#
30
1.29
43
1.1
Myeloma
13
2.06#
3
1.42
13
1.88#
11
0.98
Leukemia
18
1.52
7
1.67
16
1.19
51
2.29#
Cancers without statistically significant elevated risk are excluded, except for ones related to other statistically significant cancers; #: p value < 0.05.
